Financings Roundup
Anthera Approaches Phase III, Prices $40M Public Offering
With launch of its Phase III registration studies for Lupus drug blisibimod imminent, Anthera Pharmaceuticals Inc., of Hayward, Calif., priced an underwritten public offering worth $40 million in gross proceeds to support operations as it goes forward.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.